Changes in matrix metalloproteinase network in a spontaneous autoimmune uveitis model

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 5, 2011, Pages 2314-2320

  Hofmaier, Florian ^a   Hauck, Stefanie M ^b   Amann, Barbara ^a   Degroote, Roxane L ^a   Deeg, Cornelia A ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ANIMAL TISSUE; ARTICLE; AUTOIMMUNE UVEITIS; CELL INVASION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; EQUINE RECURRENT UVEITIS; HORSE DISEASE; HUMAN; HUMAN TISSUE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; RETINA; UPREGULATION; UVEITIS; VITREOUS BODY;

ANIMALS; AUTOIMMUNE DISEASES; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HORSE DISEASES; HORSES; LIPOCALINS; MATRIX METALLOPROTEINASES; RECURRENCE; RETINA; TISSUE INHIBITOR OF METALLOPROTEINASE-2; UVEITIS; VITREOUS BODY;

EID: 79955985778     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.10-6475     Document Type: Article

References (54)

1. Deeg CA, Hauck SM, Amann B, et al. Equine recurrent uveitis-a spontaneous horse model of uveitis. Ophthalmic Res. 2008;40: 151-153.
2. Deeg CA, Ehrenhofer M, Thurau SR, Reese S, Wildner G, Kaspers B. Immunopathology of recurrent uveitis in spontaneously diseased horses. Exp Eye Res. 2002;75:127-133.
3. Deeg CA, Hauck SM, Amann B, Kremmer E, Stangassinger M, Ueffing M. Major retinal autoantigens remain stably expressed during all stages of spontaneous uveitis. Mol Immunol. 2007;44: 3291-3296.
4. Deeg CA, Kaspers B, Gerhards H, Thurau SR, Wollanke B, Wildner G. Immune responses to retinal autoantigens and peptides in equine recurrent uveitis. Invest Ophthalmol Vis Sci. 2001;42:393-398.
5. Deeg CA, Pompetzki D, Raith AJ, et al. Identification and functional validation of novel autoantigens in equine uveitis. Mol Cell Proteomics. 2006;5:1462-1470.
6. Deeg CA. Ocular immunology in equine recurrent uveitis. Vet Ophthalmol. 2008;(Suppl 1):61-65.
7. Deeg CA, Altmann F, Hauck SM, et al. Down-regulation of pigment epithelium-derived factor in uveitic lesion associates with focal vascular endothelial growth factor expression and breakdown of the blood-retinal barrier. Proteomics. 2007;7:1540-1548.
8. Deeg CA, Thurau SR, Gerhards H, Ehrenhofer M, Wildner G, Kaspers B. Uveitis in horses induced by interphotoreceptor retinoid-binding protein is similar to the spontaneous disease. Eur J Immunol. 2002;32:2598-2606.
9. Deeg CA, Raith AJ, Amann B, et al. CRALBP is a highly prevalent autoantigen for human autoimmune uveitis. Clin Dev Immunol. 2007;2007:39245.
10. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta. 2000;1477:267-283.
11. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006;69:562-573.
12. Sivak JM, Fini ME. MMPs in the eye: emerging roles for matrix metalloproteinases in ocular physiology. Prog Retin Eye Res. 2002; 21:1-14.
13. Murphy G, Nagase H. Progress in matrix metalloproteinase research. Mol Aspects Med. 2008;29:290-308.
14. Malla N, Sjoli S, Winberg JO, Hadler-Olsen E, Uhlin-Hansen L. Biological and pathobiological functions of gelatinase dimers and complexes. Connect Tissue Res. 2008;49:180-184.
15. Goetzl EJ, Banda MJ, Leppert D. Matrix metalloproteinases in immunity. J Immunol. 1996;156:1-4.
16. Wu B, Crampton SP, Hughes CC. Wnt signaling induces matrix metalloproteinase expression and regulates T cell transmigration. Immunity. 2007;26:227-239.
17. El-Shabrawi Y, Walch A, Hermann J, Egger G, Foster CS. Inhibition of MMP-dependent chemotaxis and amelioration of experimental autoimmune uveitis with a selective metalloproteinase-2 and-9 inhibitor. J Neuroimmunol. 2004;155:13-20.
18. Zhao XL, Li GZ, Sun B, et al. MMP-mediated cleavage of betadystroglycan in myelin sheath is involved in autoimmune neuritis. Biochem Biophys Res Commun. 2010;392:551-556.
19. Caterina JJ, Yamada S, Caterina NC, et al. Inactivating mutation of the mouse tissue inhibitor of metalloproteinases-2(Timp-2) gene alters proMMP-2 activation. J Biol Chem. 2000;275:26416-26422.
20. Kudo T, Takino T, Miyamori H, Thompson EW, Sato H. Substrate choice of membrane-type 1 matrix metalloproteinase is dictated by tissue inhibitor of metalloproteinase-2 levels. Cancer Sci. 2007;98: 563-568.
21. Wang Z, Juttermann R, Soloway PD. TIMP-2 is required for efficient activation of proMMP-2 in vivo. J Biol Chem. 2000;275:26411-26415.
22. Seo DW, Li H, Guedez L, et al. TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism. Cell. 2003;114: 171-180.
23. Magnoni S, Baker A, Thomson S, et al. Neuroprotective effect of adenoviral-mediated gene transfer of TIMP-1 and-2 in ischemic brain injury. Gene Ther. 2007;14:621-625.
24. Butler GS, Butler MJ, Atkinson SJ, et al. The TIMP2 membrane type 1 metalloproteinase "receptor" regulates the concentration and efficient activation of progelatinase A: a kinetic study. J Biol Chem. 1998;273:871-880.
25. Kang D, Gho Y, Suh M, Kang C. Highly sensitive and fast protein detection with Coomassie brilliant blue in sodium dodecyl sulfatepolyacrylamide gel electrophoresis. Bull Korean Chem Soc. 2002; 23:1511-1512.
26. Riley SC, Gibson AH, Leask R, Mauchline DJ, Pedersen HG, Watson ED. Secretion of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases into follicular fluid during follicle development in equine ovaries. Reproduction. 2001;121:553-560.
27. Bergers G, Brekken R, McMahon G, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol. 2000;2:737-744.
28. Kubben FJGM, Sier CFM, Hawinkels LJAC, et al. Clinical evidence for a protective role of lipocalin-2 against MMP-9 autodegradation and the impact for gastric cancer. Eur J Cancer. 2007;43:1869-1876.
29. Rattner A, Nathans J. The genomic response to retinal disease and injury: evidence for endothelin signaling from photoreceptors to glia. J Neurosci. 2005;25:4540-4549.
30. Maatta M, Tervahartiala T, Vesti E, Airaksinen J, Sorsa T. Levels and activation of matrix metalloproteinases in aqueous humor are elevated in uveitis-related secondary glaucoma. J Glaucoma. 2006; 15:229-237.
31. Adithi M, Nalini V, Kandalam M, Krishnakumar S. Expression of matrix metalloproteinases and their inhibitors in retinoblastoma. J Pediatr Hematol Oncol. 2007;29:399-405.
32. Agapova OA, Ricard CS, Salvador-Silva M, Hernandez MR. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human optic nerve head astrocytes. Glia. 2001;33: 205-216.
33. Plantner JJ, Smine A, Quinn TA. Matrix metalloproteinases and metalloproteinase inhibitors in human interphotoreceptor matrix and vitreous. Curr Eye Res. 1998;17:132-140.
34. Woods CC, Sundar K, Tessler C, et al. Tissue inhibitor of metalloproteinase-2 inhibits T-cell infiltration and preserves pancreatic beta-cell function in an in vitro type 1 diabetes mellitus model. J Autoimmun. 2006;27:28-37.
35. Kinoshita T, Sato H, Okada A, et al. TIMP-2 promotes activation of progelatinase A by membrane-type 1 matrix metalloproteinase immobilized on agarose beads. J Biol Chem. 1998;273:16098-16103.
36. Wallace GR, Whiston RA, Stanford MR, Wells GMA, Gearing AJH, Clements JM. The matrix metalloproteinase inhibitor BB-1101 prevents experimental autoimmune uveoretinitis (EAU). Clin Exp Immunol. 1999;118:364-370.
37. Abu El-Asrar AM, Struyf S, Descamps FJ, et al. Chemokines and gelatinases in the aqueous humor of patients with active uveitis. Am J Ophthalmol. 2004;138:401-411.
38. Di Girolamo N, Verma MJ, McCluskey PJ, Lloyd A, Wakefield D. Increased matrix metalloproteinases in the aqueous humor of patients and experimental animals with uveitis. Curr Eye Res. 1996;15:1060-1068.
39. El-Shabrawi Y, Christen WG, Foster CS. Correlation of metalloproteinase-2 and-9 with proinflammatory cytokines interleukin-1, interleukin-12 and the interleukin-1 receptor antagonist in patients with chronic uveitis. Curr Eye Res. 2000;20:211-214.
40. McQuibban GA, Gong JH, Tam EM, McCulloch CA, Clark-Lewis I, Overall CM. Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science. 2000;289:1202-1206.
41. Zipplies JK, Kirschfink M, Amann B, Hauck SM, Stangassinger M, Deeg C. Complement factor B expression profile in a spontaneous uveitis model. Immunobiology. 2010;215:949-955.
42. Hollborn M, Stathopoulos C, Steffen A, Wiedemann P, Kohen L, Bringmann A. Positive feedback regulation between MMP-9 and VEGF in human RPE cells. Invest Ophthalmol Vis Sci. 2007;48: 4360-4367.
43. Abraham M, Shapiro S, Karni A, Weiner HL, Miller A. Gelatinases (MMP-2 and MMP-9) are preferentially expressed by Th1 vs. Th2 cells. J Neuroimmunol. 2005;163:157-164.
44. Lambert V, Munaut C, Jost M, et al. Matrix metalloproteinase-9 contributes to choroidal neovascularization. Am J Pathol. 2002; 161:1247-1253.
45. Mohammad G, Kowluru RA. Matrix metalloproteinase-2 in the development of diabetic retinopathy and mitochondrial dysfunction. Lab Invest. 2010;90:1365-1372.
46. Smine A, Plantner JJ. Membrane type-1 matrix metalloproteinase in human ocular tissues. Curr Eye Res. 1997;16:925-929.
47. Sariahmetoglu M, Crawford BD, Leon H, et al. Regulation of matrix metalloproteinase-2 (MMP-2) activity by phosphorylation. FASEB J. 2007;21:2486-2495.
48. Chow AK, Cena J, El-Yazbi AF, et al. Caveolin-1 inhibits matrix metalloproteinase-2 activity in the heart. J Mol Cell Cardiol. 2007; 42:896-901.
49. Hauck SM, Dietter J, Kramer RL, et al. Deciphering membraneassociated molecular processes in target tissue of autoimmune uveitis by label-free quantitative mass spectrometry. Mol Cell Proteomics. 2010;9:2292-305.
50. Yan L, Borregaard N, Kjeldsen L, Moses MA. The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL): modulation of MMP-9 activity by NGAL. J Biol Chem. 2001;276:37258-37265.
51. Ding L, Hanawa H, Ota Y, et al. Lipocalin-2/neutrophil gelatinase-B associated lipocalin is strongly induced in hearts of rats with autoimmune myocarditis and in human myocarditis. Circ J. 2010; 74:523-530.
52. Kjeldsen L, Johnsen AH, Sengelov H, Borregaard N. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem. 1993;268:10425-10432.
53. Gerhardinger C, Costa MB, Coulombe MC, Toth I, Hoehn T, Grosu P. Expression of acute-phase response proteins in retinal Muller cells in diabetes. Invest Ophthalmol Vis Sci. 2005;46:349-357.
54. Hauck SM, Schoeffmann S, Amann B, et al. Retinal Mueller glial cells trigger the hallmark inflammatory process in autoimmune uveitis. J Proteome Res. 2007;6:2121-2131.